Published in Nat Rev Cardiol on August 31, 2017
Five-Year Outcomes after On-Pump and Off-Pump Coronary-Artery Bypass. N Engl J Med (2017) 4.52
Metalloproteinases shed TREM-1 ectodomain from lipopolysaccharide-stimulated human monocytes. J Immunol (2007) 1.49
Persistent competition among stem cells and their daughters in the Drosophila ovary germline niche. Development (2009) 1.21
Monocytes from cystic fibrosis patients are locked in an LPS tolerance state: down-regulation of TREM-1 as putative underlying mechanism. PLoS One (2008) 1.08
Impaired antigen presentation and potent phagocytic activity identifying tumor-tolerant human monocytes. Biochem Biophys Res Commun (2012) 0.83
Coronary artery disease: CABG surgery or PCI for left main CAD? Nat Rev Cardiol (2016) 0.81
Surgery: Neutral results for levosimendan in cardiac surgery. Nat Rev Cardiol (2017) 0.75
Thrombosis: Rivaroxaban, a cost-effective alternative for SVT? Nat Rev Cardiol (2017) 0.75
Atrial fibrillation: New score for stroke risk. Nat Rev Cardiol (2016) 0.75
Coronary artery disease: Urbanization is a risk factor for CAD. Nat Rev Cardiol (2017) 0.75
Atherosclerosis: Treating atherosclerosis with antitumour antibodies. Nat Rev Cardiol (2016) 0.75
Stem cells: A step closer to cardiac repair therapies. Nat Rev Cardiol (2016) 0.75
Acute coronary syndromes: Microbial-dependent TMAO as a prognostic marker in ACS. Nat Rev Cardiol (2017) 0.75
Dyslipidaemia: Is CETP inhibition a viable therapeutic strategy? Nat Rev Cardiol (2017) 0.75
Vascular disease: Ticagrelor not superior to clopidogrel for PAD. Nat Rev Cardiol (2016) 0.75
Device therapy: A robotic heart sleeve to keep the beat. Nat Rev Cardiol (2017) 0.75
Thrombosis: Targeting factor XIa. Nat Rev Cardiol (2016) 0.75
Stem cells: Cell therapy improves outcomes in heart failure. Nat Rev Cardiol (2016) 0.75
Genetics: ANGPTL3 deficiency protects from CAD. Nat Rev Cardiol (2017) 0.75
Dyslipidaemia: Promising results with siRNA against PCSK9. Nat Rev Cardiol (2017) 0.75
Coronary artery disease: New polygenic risk score improves prediction of CHD. Nat Rev Cardiol (2016) 0.75
Interventional cardiology: Drug-eluting or bare-metal stents? Nat Rev Cardiol (2016) 0.75
Heart failure: Heart failure after MI might increase risk of cancer. Nat Rev Cardiol (2016) 0.75
Valvular disease: DPP4 inhibitors to prevent aortic valve calcification. Nat Rev Cardiol (2017) 0.75
Vascular disease: Carotid artery stenosis - stenting or endarterectomy? Nat Rev Cardiol (2016) 0.75
Dyslipidaemia: FH genes, beyond LDL-C, predict CAD. Nat Rev Cardiol (2016) 0.75
Cardiomyopathies: The happy heart syndrome. Nat Rev Cardiol (2016) 0.75
Thrombosis: Gut microbes modulate platelet function and thrombosis risk. Nat Rev Cardiol (2016) 0.75
Diabetes: Sacubitril/valsartan improves glycaemic control. Nat Rev Cardiol (2017) 0.75
Immunology: Surprising role of cardiac macrophages in heart electrical conduction. Nat Rev Cardiol (2017) 0.75
Diabetes: PCSK9 inhibition is not associated with new-onset diabetes. Nat Rev Cardiol (2016) 0.75
Heart failure: No effect of ularitide in heart failure outcomes. Nat Rev Cardiol (2017) 0.75
Heart failure: Interatrial shunting for the treatment of heart failure. Nat Rev Cardiol (2016) 0.75
Cardioprotection: Cardiotoxicity of anticancer therapy. Nat Rev Cardiol (2016) 0.75
Risk factors: Air pollution accelerates progression of atherosclerosis. Nat Rev Cardiol (2016) 0.75
Hypertension: Update on renal artery denervation. Nat Rev Cardiol (2016) 0.75
Metabolism: Calorie restriction for healthy ageing. Nat Rev Cardiol (2017) 0.75
Acute coronary syndromes: Plaque erosion - antithrombotics without stenting. Nat Rev Cardiol (2016) 0.75
Heart failure: No early benefits of adjunct therapy with tolvaptan for acute heart failure. Nat Rev Cardiol (2017) 0.75
Public health: Active commuting can lower your risk of CVD. Nat Rev Cardiol (2017) 0.75
Arrhythmias: Safety backups to keep the pace. Nat Rev Cardiol (2017) 0.75
Regenerative medicine: New targets for enhancing cardiac regeneration. Nat Rev Cardiol (2017) 0.75
Hypertension: Ibuprofen increases blood pressure in patients with arthritis. Nat Rev Cardiol (2017) 0.75
Growth and development: Poly(A) tail-based regulation of cardiac hypertrophy. Nat Rev Cardiol (2017) 0.75
Cardiomyopathy: Takotsubo has long-lasting functional consequences. Nat Rev Cardiol (2017) 0.75
Pharmacogenetics: Genetic approach supports cardiovascular safety of GLP1R agonists. Nat Rev Cardiol (2016) 0.75
Hypertension: Promising mitochondria-targeting drug for PAH. Nat Rev Cardiol (2017) 0.75
Risk factors: Aircraft noise impairs vascular function. Nat Rev Cardiol (2017) 0.75
Cardioprotection: IL-11 is a potential therapeutic target in cardiovascular fibrosis. Nat Rev Cardiol (2017) 0.75
Thrombosis: Novel target with antithrombotic potential and low bleeding risk. Nat Rev Cardiol (2017) 0.75
Diabetes: Further insights into SGLT2 inhibitors. Nat Rev Cardiol (2017) 0.75
Hypertension: Proof of concept for renal denervation. Nat Rev Cardiol (2017) 0.75
Imaging: Mitochondria shine light on heart function. Nat Rev Cardiol (2017) 0.75
Risk factors: Migraine - headache and heartache. Nat Rev Cardiol (2016) 0.75
Cardioprotection: Anti-ageing effects of cardiosphere-derived cells. Nat Rev Cardiol (2017) 0.75
Prevention: The healthy diet - fruits, vegetables, legumes, and fats. Nat Rev Cardiol (2017) 0.75
Dyslipidaemia: No effect of PCSK9 inhibitors on cognitive function. Nat Rev Cardiol (2017) 0.75